Agilent Technologies reported that it has agreed to purchase Biocare Medical, a privately held clinical pathology company, for $950 million in cash. Following the announcement, Agilent shares rose 1% to $115.
The company characterized the acquisition as a strategic expansion of its capabilities in immunohistochemistry - a cancer diagnostic approach that employs antibodies to detect abnormal cells. Agilent said the addition of Biocare Medical will strengthen its footprint in that area.
According to information on Biocare Medical's website, the company's development pipeline centers on integrated tissue-diagnostic tools intended for use in both cancer and infectious disease testing. The website also lists government and military laboratories among Biocare's customers.
Agilent stated the transaction will have an immediate financial impact, projecting that it will drive revenue growth and improve profit margins within the first year following closing. The company also expects the deal to increase the proportion of its sales coming from consumables and services.
The agreement remains subject to regulatory approval. Agilent indicated the transaction is expected to be completed by the end of the fourth quarter of 2026, assuming the necessary clearances are obtained.
This announcement represents a targeted expansion of Agilent's diagnostic portfolio into a segment of pathology focused on antibody-based tissue analysis. The company offered specific financial and strategic expectations tied to the deal, while leaving completion contingent on the regulatory process and the stated timetable.
Summary
Agilent will acquire Biocare Medical for $950 million in cash to bolster its immunohistochemistry offerings. The company said the purchase will improve revenue growth and margins in year one and raise the share of sales from consumables and services. The deal is expected to close by the end of the fourth quarter of 2026, pending regulatory clearance. Market reaction on the announcement was modestly positive, with Agilent shares up 1% to $115.
Key points
- Transaction value is $950 million in cash for privately held Biocare Medical.
- Acquisition targets immunohistochemistry, a diagnostic method that uses antibodies to identify abnormal cells, and intends to expand integrated tissue-diagnostic capabilities for cancer and infectious diseases.
- Agilent expects the deal to accelerate revenue growth and raise profit margins in the first year while increasing sales mix toward consumables and services; market reaction included a 1% rise in the stock to $115.
Risks and uncertainties
- The transaction is subject to regulatory clearance, and final approval is not guaranteed.
- The closing is targeted by the end of the fourth quarter of 2026, creating timing uncertainty until the deal is finalized.